Core Viewpoint - The resignation of Ren Hui, the president of Boya Bio, after less than 10 months in office, coincides with the company's forecast of a significant decline in net profit for 2025, primarily due to asset impairment from an acquisition [1][5]. Group 1: Company Leadership Changes - Ren Hui resigned from his positions as president and board member of Boya Bio due to work changes, and his resignation leaves the president position temporarily vacant [1][2]. - Ren Hui was appointed as president on May 16, 2025, and previously served as vice president starting October 23, 2024, with a reported pre-tax salary of 93,000 yuan in 2024 [2][3]. Group 2: Financial Performance - Boya Bio's 2025 annual performance forecast indicates a net profit decline of 65.62% to 73.55%, estimated between 105 million yuan and 136.5 million yuan, with a projected non-recurring net loss of 7.5 million to 15 million yuan [5][6]. - The decline in financial performance is attributed to three main factors: impairment losses from the acquisition of Green Cross Hong Kong Holdings, depreciation and amortization impacts from the acquisition, and decreased gross margins in the blood products business due to intensified market competition and regulatory changes [6][7]. Group 3: Acquisition Impact - The acquisition of Green Cross Hong Kong Holdings in November 2024 has led to significant impairment losses, totaling approximately 300 million yuan, affecting the company's financial outlook for 2025 [6][7]. - The performance of the acquired company's products, particularly hyaluronic acid, has been negatively impacted by a downturn in the market, contributing to the overall financial challenges faced by Boya Bio [6][7]. Group 4: Shareholder Actions - Despite the poor financial outlook, the controlling shareholder, China Resources Pharmaceutical Group, has increased its stake in Boya Bio, acquiring an additional 6.0509 million shares, representing 1.20% of the total share capital [4][6]. - The stock price of Boya Bio has been on a downward trend since October 2024, with a significant drop from a peak of 41.51 yuan to a closing price of 22.25 yuan as of February 27, 2026, resulting in a market capitalization of approximately 11.22 billion yuan [6][7].